drugset

drugset / Trial / NCT05702034

A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

NCT05702034 ↗

Phase 3 Active not recruiting 12532 enrolled Janssen Research & Development, LLC Bristol Myers Squibb Company (BMS) · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.

Timeline

Start: 2023-02-15
Primary completion: 2026-11-11
Completion: 2026-12-09

Publications

Weitz JI, Harrington RA; LIBREXIA Program Executive Council. Rationale for the milvexian dosing in the phase 3 LIBREXIA program. J Thromb Haemost. 2026 Jun;24(6):2158-2169. doi: 10.1016/j.jtha.2026.02.020. Epub 2026 Mar 4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Milvexian	Small molecule	25 mg	Oral

Indications